Plant Name: Miliusa sinensis
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| GPR35; | |
| TDP1; ALPI; ALPL; RECQL; BLM; HPGD; AKR1B1; HSD17B10; ALOX15; ALDH1A1; USP2; APEX1; CD38; POLB; | |
| DUSP3; | |
| GAA; | |
| BRAF; FLT4; TEK; PDGFRB; INSR; MAP3K8; AKT1; MET; PLK4; EGFR; ERBB2; AURKB; NUAK1; EPHB4; AURKA; PLK1; KDR; GSK3B; SRC; IGF1R; PTK2; CSNK2A1; | |
| CA2; CA6; CA12; CA9; CA13; CA14; CA5A; CA3; CA5B; CA4; CA1; CA7; | |
| KDM4E; | |
| BACE1; | |
| NFKB1; | |
| FUT7; | |
| SLC22A6; | |
| SMAD3; LMNA; MAPT; HBB; HSPA1A; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: |
|---|
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Aspartic protease | BACE1 | Beta-secretase 1 | P56817 | CHEMBL4822 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | ALPI | Intestinal alkaline phosphatase | P09923 | CHEMBL5573 |
| Enzyme_unclassified | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P05186 | CHEMBL5979 |
| Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
| Enzyme_unclassified | BLM | Bloom syndrome protein | P54132 | CHEMBL1293237 |
| Enzyme_unclassified | HPGD | 15-hydroxyprostaglandin dehydrogenase [NAD+] | P15428 | CHEMBL1293255 |
| Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
| Enzyme_unclassified | USP2 | Ubiquitin carboxyl-terminal hydrolase 2 | O75604 | CHEMBL1293227 |
| Enzyme_unclassified | APEX1 | DNA-(apurinic or apyrimidinic site) lyase | P27695 | CHEMBL5619 |
| Enzyme_unclassified | CD38 | Lymphocyte differentiation antigen CD38 | P28907 | CHEMBL4660 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Hydrolase | GAA | Lysosomal alpha-glucosidase | P10253 | CHEMBL2608 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA13 | Carbonic anhydrase XIII | Q8N1Q1 | CHEMBL3912 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Lyase | CA5A | Carbonic anhydrase VA | P35218 | CHEMBL4789 |
| Lyase | CA3 | Carbonic anhydrase III | P07451 | CHEMBL2885 |
| Lyase | CA5B | Carbonic anhydrase VB | Q9Y2D0 | CHEMBL3969 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
| Protein Kinase | BRAF | Serine/threonine-protein kinase B-raf | P15056 | CHEMBL5145 |
| Protein Kinase | FLT4 | Vascular endothelial growth factor receptor 3 | P35916 | CHEMBL1955 |
| Protein Kinase | TEK | Tyrosine-protein kinase TIE-2 | Q02763 | CHEMBL4128 |
| Protein Kinase | PDGFRB | Platelet-derived growth factor receptor beta | P09619 | CHEMBL1913 |
| Protein Kinase | INSR | Insulin receptor | P06213 | CHEMBL1981 |
| Protein Kinase | MAP3K8 | Mitogen-activated protein kinase kinase kinase 8 | P41279 | CHEMBL4899 |
| Protein Kinase | AKT1 | Serine/threonine-protein kinase AKT | P31749 | CHEMBL4282 |
| Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
| Protein Kinase | PLK4 | Serine/threonine-protein kinase PLK4 | O00444 | CHEMBL3788 |
| Protein Kinase | EGFR | Epidermal growth factor receptor erbB1 | P00533 | CHEMBL203 |
| Protein Kinase | ERBB2 | Receptor protein-tyrosine kinase erbB-2 | P04626 | CHEMBL1824 |
| Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
| Protein Kinase | NUAK1 | NUAK family SNF1-like kinase 1 | O60285 | CHEMBL5784 |
| Protein Kinase | EPHB4 | Ephrin type-B receptor 4 | P54760 | CHEMBL5147 |
| Protein Kinase | AURKA | Serine/threonine-protein kinase Aurora-A | O14965 | CHEMBL4722 |
| Protein Kinase | PLK1 | Serine/threonine-protein kinase PLK1 | P53350 | CHEMBL3024 |
| Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
| Protein Kinase | GSK3B | Glycogen synthase kinase-3 beta | P49841 | CHEMBL262 |
| Protein Kinase | SRC | Tyrosine-protein kinase SRC | P12931 | CHEMBL267 |
| Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
| Protein Kinase | PTK2 | Focal adhesion kinase 1 | Q05397 | CHEMBL2695 |
| Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
| Protein Phosphatase | DUSP3 | Dual specificity protein phosphatase 3 | P51452 | CHEMBL2635 |
| SLC superfamily of solute carriers | SLC22A6 | Solute carrier family 22 member 6 | Q4U2R8 | CHEMBL1641347 |
| Small molecule receptor (family A GPCR) | GPR35 | G-protein coupled receptor 35 | Q9HC97 | CHEMBL1293267 |
| Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
| Transferase | FUT7 | Alpha-(1,3)-fucosyltransferase 7 | Q11130 | CHEMBL3596077 |
| Unclassified | SMAD3 | Mothers against decapentaplegic homolog 3 | P84022 | CHEMBL1293258 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
| Unclassified | HBB | Hemoglobin beta chain | P68871 | CHEMBL4331 |
| Unclassified | HSPA1A | Heat shock 70 kDa protein 1 | P0DMV8 | CHEMBL5460 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0005488; binding | GO:0005524; ATP binding | 5.970E-13 | 4.482E-10 | AKT1, AURKA, AURKB, BLM, BRAF, CSNK2A1, EGFR, EPHB4, ERBB2, FLT4, GSK3B, HSPA1A, IGF1R, INSR, KDR, MAP3K8, MET, NUAK1, PDGFRB, PLK1, PLK4, PTK2, RECQL, SRC, TEK |
| BP | GO:0008152; metabolic process | GO:0038083; peptidyl-tyrosine autophosphorylation | 7.482E-09 | 1.987E-06 | EGFR, IGF1R, INSR, KDR, PTK2, SRC |
| MF | GO:0005488; binding | GO:0019838; growth factor binding | 7.395E-09 | 1.987E-06 | EGFR, ERBB2, FLT4, IGF1R, INSR, KDR, PDGFRB, TEK |
| MF | Unclassified; | GO:0004716; signal transducer, downstream of receptor, with protein tyrosine kinase activity | 1.121E-08 | 2.776E-06 | EGFR, ERBB2, INSR, KDR |
| BP | GO:0009987; cellular process | GO:0051897; positive regulation of protein kinase B signaling | 2.528E-08 | 5.243E-06 | EGFR, ERBB2, INSR, MET, PDGFRB, PTK2, SRC, TEK |
| CC | GO:0016020; membrane | GO:0016323; basolateral plasma membrane | 1.211E-07 | 2.109E-05 | CA2, CA4, CA9, EGFR, ERBB2, HPGD, SLC22A6, TEK |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 1.748E-07 | 2.840E-05 | ALPI, BLM, CA1, CA12, CA13, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, SMAD3 |
| BP | GO:0008152; metabolic process | GO:0045429; positive regulation of nitric oxide biosynthetic process | 1.825E-07 | 2.921E-05 | AKT1, EGFR, HBB, INSR, SMAD3 |
| BP | GO:0009987; cellular process | GO:0070374; positive regulation of ERK1 and ERK2 cascade | 1.883E-07 | 2.971E-05 | ALOX15, BRAF, EGFR, FLT4, KDR, PDGFRB, SRC, TEK |
| MF | GO:0005488; binding | GO:0042802; identical protein binding | 3.380E-07 | 4.939E-05 | AKT1, BLM, BRAF, CD38, CSNK2A1, EGFR, ERBB2, FLT4, HPGD, IGF1R, KDR, MAPT, MET, NFKB1, PLK1, PLK4, SLC22A6, SMAD3, USP2 |
| MF | GO:0005488; binding | GO:0019901; protein kinase binding | 1.686E-06 | 1.932E-04 | AKT1, AURKA, BRAF, DUSP3, EGFR, GSK3B, PDGFRB, PLK1, PTK2, SMAD3, SRC |
| MF | GO:0005488; binding | GO:0019903; protein phosphatase binding | 1.931E-06 | 2.201E-04 | AKT1, EGFR, ERBB2, FLT4, MAPT, MET |
| BP | GO:0008152; metabolic process | GO:0043552; positive regulation of phosphatidylinositol 3-kinase activity | 2.319E-06 | 2.603E-04 | PDGFRB, PTK2, SRC, TEK |
| BP | GO:0009987; cellular process | GO:0035690; cellular response to drug | 2.815E-06 | 3.128E-04 | AKR1B1, APEX1, BLM, BRAF, EGFR, KDR, NFKB1, SRC |
| BP | GO:0032501; multicellular organismal process | GO:0003007; heart morphogenesis | 3.029E-06 | 3.331E-04 | EPHB4, GAA, INSR, PTK2 |
| BP | GO:0008283; cell proliferation | GO:0048661; positive regulation of smooth muscle cell proliferation | 4.133E-06 | 4.348E-04 | AKR1B1, AKT1, EGFR, HPGD, PDGFRB |
| BP | GO:0050896; response to stimulus | GO:0042060; wound healing | 4.410E-06 | 4.595E-04 | ALOX15, EGFR, ERBB2, PDGFRB, SMAD3 |
| BP | GO:0050896; response to stimulus | GO:0034405; response to fluid shear stress | 5.498E-06 | 5.568E-04 | AKT1, CA2, PDGFRB, SRC |
| BP | GO:0008152; metabolic process | GO:0032436; positive regulation of proteasomal ubiquitin-dependent protein catabolic process | 5.664E-06 | 5.710E-04 | AKT1, AURKA, GSK3B, HSPA1A, PLK1 |
| BP | Unclassified; | GO:0006461; protein complex assembly | 5.861E-06 | 5.855E-04 | BLM, BRAF, GSK3B, HBB, HSD17B10, HSPA1A, IGF1R, INSR, MAPT, PTK2, SLC22A6, SMAD3, SRC, TEK |
| BP | GO:0050896; response to stimulus | GO:0001101; response to acid chemical | 7.469E-06 | 7.164E-04 | AKR1B1, AKT1, CD38, EGFR, KDR, PDGFRB, SLC22A6, SRC |
| BP | GO:0009987; cellular process | GO:0006286; base-excision repair, base-free sugar-phosphate removal | 9.810E-06 | 9.090E-04 | APEX1, POLB |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 1.402E-28 | 3.053E-24 | CA1, CA12, CA13, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
| BP | GO:0009987; cellular process | GO:0038084; vascular endothelial growth factor signaling pathway | 1.327E-05 | 1.165E-03 | FLT4, KDR, PDGFRB |
| BP | GO:0009987; cellular process | GO:1901796; regulation of signal transduction by p53 class mediator | 1.926E-05 | 1.583E-03 | AKT1, AURKA, AURKB, BLM, CSNK2A1, NUAK1 |
| BP | GO:0050896; response to stimulus | GO:0042542; response to hydrogen peroxide | 2.309E-05 | 1.862E-03 | AKR1B1, APEX1, HBB, PDGFRB, SRC |
| BP | GO:0050896; response to stimulus | GO:0034614; cellular response to reactive oxygen species | 2.309E-05 | 1.862E-03 | AKR1B1, AKT1, APEX1, EGFR, SRC |
| BP | GO:0009987; cellular process | GO:0051259; protein oligomerization | 2.352E-05 | 1.883E-03 | BLM, BRAF, HBB, HSD17B10, IGF1R, INSR, MAPT, SLC22A6, TEK |
| CC | GO:0043226; organelle | GO:0005876; spindle microtubule | 2.347E-05 | 1.883E-03 | AURKA, AURKB, PLK1, POLB |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 2.937E-05 | 2.292E-03 | CA2, CA7 |
| CC | GO:0016020; membrane | GO:0045121; membrane raft | 3.724E-05 | 2.806E-03 | BACE1, EGFR, INSR, KDR, SLC22A6, SRC, TEK |
| CC | GO:0044464; cell part | GO:0005829; cytosol | 4.555E-05 | 3.274E-03 | AKR1B1, AKT1, ALDH1A1, ALOX15, AURKA, AURKB, BLM, BRAF, CA1, CA13, CA2, CA3, CA7, CSNK2A1, DUSP3, EPHB4, ERBB2, GSK3B, HBB, HPGD, HSPA1A, LMNA, MAP3K8, MAPT, NFKB1, PLK1, PLK4, PTK2, SMAD3, SRC |
| BP | GO:0065007; biological regulation | GO:0051881; regulation of mitochondrial membrane potential | 4.963E-05 | 3.520E-03 | AKT1, KDR, MAPT, SRC |
| BP | GO:0009987; cellular process | GO:0014068; positive regulation of phosphatidylinositol 3-kinase signaling | 5.603E-05 | 3.886E-03 | KDR, PDGFRB, PTK2, TEK |
| BP | GO:0051179; localization | GO:1900182; positive regulation of protein localization to nucleus | 5.622E-05 | 3.886E-03 | AKT1, EGFR, PLK1, SMAD3, SRC |
| MF | GO:0003824; catalytic activity | GO:0046934; phosphatidylinositol-4,5-bisphosphate 3-kinase activity | 5.603E-05 | 3.886E-03 | EGFR, ERBB2, MET, PDGFRB |
| BP | GO:0065007; biological regulation | GO:0044092; negative regulation of molecular function | 5.944E-05 | 4.025E-03 | AKT1, AURKA, AURKB, CSNK2A1, DUSP3, GPR35, GSK3B, IGF1R, MAPT, MET, NFKB1, PLK1, SRC |
| BP | GO:0009987; cellular process | GO:0009968; negative regulation of signal transduction | 6.949E-05 | 4.642E-03 | AKT1, BRAF, DUSP3, EGFR, ERBB2, GSK3B, HSPA1A, IGF1R, LMNA, MET, PDGFRB, SMAD3, SRC |
| BP | GO:0009987; cellular process | GO:0048010; vascular endothelial growth factor receptor signaling pathway | 7.886E-05 | 5.051E-03 | FLT4, KDR, PTK2, SRC |
| BP | GO:0008152; metabolic process | GO:0006650; glycerophospholipid metabolic process | 8.821E-05 | 5.584E-03 | ALOX15, ALPI, CSNK2A1, EGFR, ERBB2, MET, PDGFRB |
| MF | GO:0003824; catalytic activity | GO:0009378; four-way junction helicase activity | 9.750E-05 | 6.032E-03 | BLM, RECQL |
| CC | GO:0032991; macromolecular complex | GO:0032133; chromosome passenger complex | 9.750E-05 | 6.032E-03 | AURKA, AURKB |
| MF | GO:0005488; binding | GO:0043548; phosphatidylinositol 3-kinase binding | 1.033E-04 | 6.353E-03 | IGF1R, INSR, PDGFRB |
| BP | GO:0009987; cellular process | GO:0071407; cellular response to organic cyclic compound | 1.157E-04 | 7.020E-03 | AKT1, ALPL, APEX1, BLM, EGFR, NFKB1, SRC |
| BP | GO:0050896; response to stimulus | GO:1901655; cellular response to ketone | 1.249E-04 | 7.408E-03 | AKR1B1, AKT1, EGFR, SRC |
| CC | GO:0043226; organelle | GO:0051233; spindle midzone | 1.265E-04 | 7.423E-03 | AURKA, AURKB, PLK1 |
| BP | GO:0032502; developmental process | GO:0051094; positive regulation of developmental process | 1.322E-04 | 7.719E-03 | AKT1, AURKA, BRAF, CA2, INSR, KDR, LMNA, MAPT, NFKB1, PDGFRB, SMAD3, SRC, TEK |
| BP | GO:0065007; biological regulation | GO:0031647; regulation of protein stability | 1.326E-04 | 7.719E-03 | AURKA, HSPA1A, PLK1, SMAD3, SRC, USP2 |
| MF | GO:0098772; molecular function regulator | GO:0005088; Ras guanyl-nucleotide exchange factor activity | 1.326E-04 | 7.719E-03 | EGFR, ERBB2, MET, PDGFRB, PTK2, TEK |
| MF | GO:0005488; binding | GO:0051879; Hsp90 protein binding | 1.392E-04 | 8.085E-03 | CSNK2A1, KDR, MAPT |
| BP | GO:0008152; metabolic process | GO:2001300; lipoxin metabolic process | 1.460E-04 | 8.320E-03 | ALOX15, HPGD |
| MF | GO:0003824; catalytic activity | GO:0035174; histone serine kinase activity | 1.460E-04 | 8.320E-03 | AURKA, AURKB |
| MF | GO:0003824; catalytic activity | GO:0004064; arylesterase activity | 1.460E-04 | 8.320E-03 | CA1, CA2 |
| MF | GO:0003824; catalytic activity | GO:0004035; alkaline phosphatase activity | 1.460E-04 | 8.320E-03 | ALPI, ALPL |
| MF | GO:0005488; binding | GO:0042562; hormone binding | 1.505E-04 | 8.558E-03 | ALDH1A1, EGFR, IGF1R, INSR |
| BP | Unclassified; | GO:0045907; positive regulation of vasoconstriction | 1.528E-04 | 8.621E-03 | AKT1, CD38, EGFR |
| BP | GO:0032502; developmental process | GO:0001525; angiogenesis | 1.542E-04 | 8.675E-03 | EPHB4, FLT4, KDR, PDGFRB, PTK2, TEK |
| BP | GO:0008283; cell proliferation | GO:0001938; positive regulation of endothelial cell proliferation | 1.575E-04 | 8.817E-03 | AKT1, FLT4, KDR, TEK |
| BP | GO:0050896; response to stimulus | GO:0071375; cellular response to peptide hormone stimulus | 1.589E-04 | 8.869E-03 | AKT1, APEX1, INSR, NFKB1, SRC |
| BP | GO:0065007; biological regulation | GO:0048878; chemical homeostasis | 1.631E-04 | 9.061E-03 | AKR1B1, AKT1, CA12, CA2, CA7, CD38, EGFR, GPR35, INSR, MET, SMAD3 |
| BP | GO:0050896; response to stimulus | GO:0001666; response to hypoxia | 1.642E-04 | 9.101E-03 | AKT1, CD38, LMNA, SMAD3, SRC, TEK |
| BP | GO:0065007; biological regulation | GO:0032148; activation of protein kinase B activity | 1.672E-04 | 9.196E-03 | AKT1, INSR, SRC |
| BP | GO:0065007; biological regulation | GO:0051348; negative regulation of transferase activity | 1.684E-04 | 9.239E-03 | AKT1, DUSP3, GSK3B, IGF1R, MAPT, PLK1, SRC |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 3.807E-23 | 4.145E-19 | CA1, CA12, CA13, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, HBB |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 6.784E-20 | 2.954E-16 | CA1, CA12, CA13, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 1.251E-27 | 1.988E-25 | CA12; CA1; CA3; CA5B; CA2; CA5A; CA4; CA7; CA6; CA9; CA14; CA13 |
| hsa04510 | Focal adhesion_Homo sapiens_hsa04510 | 9.166E-13 | 7.287E-11 | PDGFRB; GSK3B; SRC; FLT4; ERBB2; KDR; AKT1; BRAF; MET; PTK2; EGFR; IGF1R |
| hsa04015 | Rap1 signaling pathway_Homo sapiens_hsa04015 | 3.657E-11 | 1.938E-09 | PDGFRB; SRC; INSR; FLT4; KDR; AKT1; BRAF; TEK; MET; EGFR; IGF1R |
| hsa04151 | PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | 4.100E-10 | 1.086E-08 | PDGFRB; GSK3B; INSR; FLT4; KDR; AKT1; TEK; MET; PTK2; EGFR; NFKB1; IGF1R |
| hsa04520 | Adherens junction_Homo sapiens_hsa04520 | 5.990E-11 | 2.381E-09 | SMAD3; CSNK2A1; SRC; INSR; ERBB2; MET; EGFR; IGF1R |
| hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 2.709E-10 | 8.616E-09 | PDGFRB; GSK3B; ERBB2; AKT1; BRAF; EGFR; NFKB1; IGF1R |
| hsa04014 | Ras signaling pathway_Homo sapiens_hsa04014 | 1.582E-09 | 3.594E-08 | PDGFRB; INSR; FLT4; KDR; AKT1; TEK; MET; EGFR; NFKB1; IGF1R |
| hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 1.052E-08 | 1.673E-07 | SRC; ERBB2; KDR; AKT1; BRAF; MET; PTK2; EGFR; IGF1R |
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 2.819E-08 | 3.735E-07 | PDGFRB; GSK3B; SMAD3; ERBB2; AKT1; BRAF; MET; EGFR; NFKB1; PTK2; IGF1R |
| hsa04068 | FoxO signaling pathway_Homo sapiens_hsa04068 | 6.774E-09 | 1.346E-07 | PLK4; SMAD3; INSR; PLK1; AKT1; BRAF; EGFR; IGF1R |
| hsa04012 | ErbB signaling pathway_Homo sapiens_hsa04012 | 8.315E-09 | 1.469E-07 | GSK3B; SRC; ERBB2; AKT1; BRAF; EGFR; PTK2 |
| hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 2.715E-08 | 3.735E-07 | INSR; ERBB2; AKT1; TEK; EGFR; NFKB1; IGF1R |
| hsa04010 | MAPK signaling pathway_Homo sapiens_hsa04010 | 7.523E-08 | 8.140E-07 | PDGFRB; DUSP3; AKT1; BRAF; MAP3K8; MAPT; EGFR; NFKB1; HSPA1A |
| hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 4.930E-08 | 6.030E-07 | SMAD3; ERBB2; AKT1; BRAF; EGFR; NFKB1 |
| hsa05218 | Melanoma_Homo sapiens_hsa05218 | 7.680E-08 | 8.140E-07 | PDGFRB; AKT1; BRAF; MET; EGFR; IGF1R |
| hsa05214 | Glioma_Homo sapiens_hsa05214 | 1.603E-06 | 1.499E-05 | PDGFRB; AKT1; BRAF; EGFR; IGF1R |
| hsa05213 | Endometrial cancer_Homo sapiens_hsa05213 | 5.198E-07 | 5.165E-06 | GSK3B; ERBB2; AKT1; BRAF; EGFR |
| hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 1.865E-06 | 1.648E-05 | PDGFRB; ERBB2; AKT1; MET; EGFR |
| hsa04144 | Endocytosis_Homo sapiens_hsa04144 | 1.354E-05 | 1.076E-04 | SMAD3; SRC; KDR; MET; EGFR; HSPA1A; IGF1R |
| hsa04062 | Chemokine signaling pathway_Homo sapiens_hsa04062 | 2.234E-05 | 1.691E-04 | GSK3B; SRC; AKT1; BRAF; NFKB1; PTK2 |
| hsa05169 | Epstein-Barr virus infection_Homo sapiens_hsa05169 | 3.447E-05 | 2.377E-04 | GSK3B; CSNK2A1; AKT1; CD38; NFKB1; HSPA1A |
| hsa05223 | Non-small cell lung cancer_Homo sapiens_hsa05223 | 2.554E-05 | 1.846E-04 | ERBB2; AKT1; BRAF; EGFR |
| hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 7.288E-06 | 6.099E-05 | SRC; ERBB2; BRAF; EGFR |
| hsa04370 | VEGF signaling pathway_Homo sapiens_hsa04370 | 3.588E-05 | 2.377E-04 | SRC; KDR; AKT1; PTK2 |
| hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 5.322E-05 | 3.130E-04 | GSK3B; AKT1; BRAF; EGFR; NFKB1 |
| hsa05162 | Measles_Homo sapiens_hsa05162 | 5.918E-05 | 3.245E-04 | GSK3B; CSNK2A1; AKT1; NFKB1; HSPA1A |
| hsa05210 | Colorectal cancer_Homo sapiens_hsa05210 | 3.827E-05 | 2.434E-04 | GSK3B; SMAD3; AKT1; BRAF |
| hsa04213 | Longevity regulating pathway - multiple species_Homo sapiens_hsa04213 | 4.339E-05 | 2.654E-04 | INSR; AKT1; HSPA1A; IGF1R |
| hsa05166 | HTLV-I infection_Homo sapiens_hsa05166 | 1.333E-04 | 6.623E-04 | PDGFRB; POLB; GSK3B; SMAD3; AKT1; NFKB1 |
| hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 6.899E-05 | 3.657E-04 | GSK3B; SRC; AKT1; NFKB1 |
| hsa05120 | Epithelial cell signaling in Helicobacter pylori infection_Homo sapiens_hsa05120 | 5.511E-05 | 3.130E-04 | SRC; MET; EGFR; NFKB1 |
| hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 7.283E-05 | 3.735E-04 | SMAD3; AKT1; BRAF; NFKB1 |
| hsa04211 | Longevity regulating pathway - mammal_Homo sapiens_hsa04211 | 1.945E-04 | 9.373E-04 | INSR; AKT1; NFKB1; IGF1R |
| hsa04914 | Progesterone-mediated oocyte maturation_Homo sapiens_hsa04914 | 2.283E-04 | 1.037E-03 | PLK1; AKT1; BRAF; IGF1R |
| hsa05202 | Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | 2.210E-04 | 1.033E-03 | HPGD; MET; NFKB1; PTK2; IGF1R |
| hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 2.374E-04 | 1.049E-03 | SRC; AKT1; EGFR; HSPA1A |
| hsa04810 | Regulation of actin cytoskeleton_Homo sapiens_hsa04810 | 4.894E-04 | 1.964E-03 | PDGFRB; SRC; BRAF; PTK2; EGFR |
| hsa04660 | T cell receptor signaling pathway_Homo sapiens_hsa04660 | 2.867E-04 | 1.232E-03 | GSK3B; AKT1; MAP3K8; NFKB1 |
| hsa04931 | Insulin resistance_Homo sapiens_hsa04931 | 3.430E-04 | 1.435E-03 | GSK3B; INSR; AKT1; NFKB1 |
| hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 4.940E-04 | 1.964E-03 | GSK3B; AKT1; BRAF; NFKB1 |
| hsa04360 | Axon guidance_Homo sapiens_hsa04360 | 6.117E-04 | 2.372E-03 | GSK3B; MET; PTK2; EPHB4 |
| hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 1.030E-03 | 3.484E-03 | SMAD3; SRC; AKT1; NFKB1 |
| hsa04072 | Phospholipase D signaling pathway_Homo sapiens_hsa04072 | 9.784E-04 | 3.382E-03 | PDGFRB; INSR; AKT1; EGFR |
| hsa04550 | Signaling pathways regulating pluripotency of stem cells_Homo sapiens_hsa04550 | 9.288E-04 | 3.282E-03 | GSK3B; SMAD3; AKT1; IGF1R |
| hsa04910 | Insulin signaling pathway_Homo sapiens_hsa04910 | 8.578E-04 | 3.100E-03 | GSK3B; INSR; AKT1; BRAF |
| hsa04932 | Non-alcoholic fatty liver disease (NAFLD)_Homo sapiens_hsa04932 | 1.167E-03 | 3.786E-03 | GSK3B; INSR; AKT1; NFKB1 |
| hsa04060 | Cytokine-cytokine receptor interaction_Homo sapiens_hsa04060 | 1.278E-03 | 4.063E-03 | PDGFRB; FLT4; KDR; MET; EGFR |
| hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 2.106E-03 | 6.089E-03 | PDGFRB; ERBB2; MET; EGFR; NFKB1 |
| hsa05164 | Influenza A_Homo sapiens_hsa05164 | 2.004E-03 | 5.902E-03 | GSK3B; AKT1; NFKB1; HSPA1A |
| hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 1.727E-03 | 5.236E-03 | BACE1; GSK3B; MAPT; HSD17B10 |
| hsa04020 | Calcium signaling pathway_Homo sapiens_hsa04020 | 2.220E-03 | 6.197E-03 | PDGFRB; ERBB2; CD38; EGFR |
| hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 7.025E-04 | 2.660E-03 | AKT1; BRAF; NFKB1 |
| hsa04662 | B cell receptor signaling pathway_Homo sapiens_hsa04662 | 1.442E-03 | 4.497E-03 | GSK3B; AKT1; NFKB1 |
| hsa04933 | AGE-RAGE signaling pathway in diabetic complications_Homo sapiens_hsa04933 | 3.638E-03 | 9.484E-03 | SMAD3; AKT1; NFKB1 |
| hsa05211 | Renal cell carcinoma_Homo sapiens_hsa05211 | 1.077E-03 | 3.569E-03 | AKT1; BRAF; MET |
| hsa05231 | Choline metabolism in cancer_Homo sapiens_hsa05231 | 3.638E-03 | 9.484E-03 | PDGFRB; AKT1; EGFR |
| hsa04620 | Toll-like receptor signaling pathway_Homo sapiens_hsa04620 | 4.167E-03 | 1.035E-02 | AKT1; MAP3K8; NFKB1 |
| hsa05100 | Bacterial invasion of epithelial cells_Homo sapiens_hsa05100 | 1.745E-03 | 5.236E-03 | SRC; MET; PTK2 |
| hsa04668 | TNF signaling pathway_Homo sapiens_hsa04668 | 4.622E-03 | 1.113E-02 | AKT1; MAP3K8; NFKB1 |
| hsa05142 | Chagas disease (American trypanosomiasis)_Homo sapiens_hsa05142 | 3.950E-03 | 9.970E-03 | SMAD3; AKT1; NFKB1 |
| hsa05222 | Small cell lung cancer_Homo sapiens_hsa05222 | 2.308E-03 | 6.327E-03 | AKT1; NFKB1; PTK2 |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 8.986E-03 | 1.957E-02 | LMNA; AKT1; NFKB1 |
| hsa04540 | Gap junction_Homo sapiens_hsa04540 | 2.464E-03 | 6.640E-03 | PDGFRB; SRC; EGFR |
| hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 5.618E-03 | 1.314E-02 | GSK3B; SRC; AKT1 |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 1.233E-02 | 2.508E-02 | FUT7; GAA; ALOX15; ALDH1A1; CD38; AKR1B1; ALPL; ALPI; HSD17B10 |
| hsa04114 | Oocyte meiosis_Homo sapiens_hsa04114 | 6.302E-03 | 1.443E-02 | PLK1; AURKA; IGF1R |
| hsa05145 | Toxoplasmosis_Homo sapiens_hsa05145 | 5.618E-03 | 1.314E-02 | AKT1; NFKB1; HSPA1A |
| hsa04152 | AMPK signaling pathway_Homo sapiens_hsa04152 | 6.444E-03 | 1.443E-02 | INSR; AKT1; IGF1R |
| hsa04310 | Wnt signaling pathway_Homo sapiens_hsa04310 | 9.340E-03 | 2.007E-02 | GSK3B; SMAD3; CSNK2A1 |
| hsa04530 | Tight junction_Homo sapiens_hsa04530 | 8.813E-03 | 1.946E-02 | CSNK2A1; SRC; AKT1 |
| hsa04110 | Cell cycle_Homo sapiens_hsa04110 | 6.444E-03 | 1.443E-02 | GSK3B; SMAD3; PLK1 |
| hsa04921 | Oxytocin signaling pathway_Homo sapiens_hsa04921 | 1.246E-02 | 2.508E-02 | SRC; CD38; EGFR |
| hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 2.473E-02 | 4.467E-02 | POLB; SRC; NFKB1 |
| hsa05152 | Tuberculosis_Homo sapiens_hsa05152 | 1.711E-02 | 3.200E-02 | SRC; AKT1; NFKB1 |
| hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 2.290E-02 | 4.185E-02 | AKT1; BRAF; NFKB1 |
| hsa04920 | Adipocytokine signaling pathway_Homo sapiens_hsa04920 | 1.935E-02 | 3.577E-02 | AKT1; NFKB1 |
| hsa04150 | mTOR signaling pathway_Homo sapiens_hsa04150 | 1.446E-02 | 2.804E-02 | AKT1; BRAF |
| hsa04730 | Long-term depression_Homo sapiens_hsa04730 | 1.446E-02 | 2.804E-02 | BRAF; IGF1R |
| hsa05321 | Inflammatory bowel disease (IBD)_Homo sapiens_hsa05321 | 1.683E-02 | 3.185E-02 | SMAD3; NFKB1 |
| hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 1.268E-02 | 2.520E-02 | INSR; AKT1 |
| hsa05131 | Shigellosis_Homo sapiens_hsa05131 | 1.683E-02 | 3.185E-02 | SRC; NFKB1 |
| hsa05134 | Legionellosis_Homo sapiens_hsa05134 | 1.225E-02 | 2.508E-02 | NFKB1; HSPA1A |
| hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 1.020E-02 | 2.135E-02 | INSR; IGF1R |
| hsa05144 | Malaria_Homo sapiens_hsa05144 | 9.814E-03 | 2.081E-02 | HBB; MET |
| hsa00052 | Galactose metabolism_Homo sapiens_hsa00052 | 3.768E-03 | 9.662E-03 | GAA; AKR1B1 |
| hsa03410 | Base excision repair_Homo sapiens_hsa03410 | 4.546E-03 | 1.112E-02 | POLB; APEX1 |
| hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 2.221E-03 | 6.197E-03 | CA2; CA4 |
| hsa00790 | Folate biosynthesis_Homo sapiens_hsa00790 | 8.133E-04 | 3.007E-03 | ALPL; ALPI |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| S00-T88: Injury, poisoning and certain other consequences of external causes | Vascular restinosis following vascular graft surgery | T82.858A | FLT4 |
| C00-D49: Neoplasms | Inflammatory breast cancer | C50 | EGFR |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | INSR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | INSR; NFKB1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | INSR |
| C00-D49: Neoplasms | Esophageal cancer | C15 | EGFR |
| C00-D49: Neoplasms | Urethral cancer | NA | EGFR |
| C00-D49: Neoplasms | Haematological malignancies | C81-C86 | AURKA |
| H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | PDGFRB; INSR; AKR1B1; GSK3B |
| C00-D49: Neoplasms | Bladder cancer | C67 | EGFR; ERBB2 |
| C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Beta thalassemia | D56.1 | HBB |
| C00-D49: Neoplasms | Metastatic melanoma | C43 | BRAF; BRAF |
| C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR; EGFR |
| C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET |
| C00-D49: Neoplasms | Breast cancer | C50 | INSR; KDR; KDR; KDR; CA9; EGFR; EGFR; EGFR; ERBB2; ERBB2; ERBB2; IGF1R |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | KDR; KDR; EGFR; EGFR; EGFR; AKR1B1 |
| C00-D49: Neoplasms | Head and neck squamous cell carcinoma | C44 | EGFR |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; CA1 |
| C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR |
| K00-K95: Diseases of the digestive system | Crohn's disease | K50 | INSR |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | SRC; EGFR; EGFR |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Brain injury | S09.90 | PDGFRB |
| C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | KDR |
| C00-D49: Neoplasms | Mesothelioma | C45 | PTK2 |
| C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; CA4 |
| C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR; ERBB2 |
| K00-K95: Diseases of the digestive system | Gastrointestinal disease | K00-K93 | EGFR |
| Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Genetic disease | Q00-Q99 | ALPL |
| C00-D49: Neoplasms | Advanced cancers | C00-C96 | EGFR |
| C00-D49: Neoplasms | Cancer | C00-C96 | FLT4; TEK; AKT1; MET; KDR; SRC; CA9; NFKB1; EGFR; ERBB2; ERBB2; CD38; EPHB4; PLK1; GSK3B; IGF1R; PTK2; BRAF; BRAF; AURKA; CA1; CSNK2A1 |
| C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR |
| C00-D49: Neoplasms | Melanoma | C43 | KDR; KDR; EGFR; BRAF |
| C00-D49: Neoplasms | Malignant tumor | C00-C75, C7A, C7B | EGFR |
| C00-D49: Neoplasms | Glioblastoma multiforme | C71 | SRC; EGFR; EGFR; ERBB2 |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | AKR1B1; CA1; CA1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | EGFR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1 |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | SRC |
| C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; KDR |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | KDR |
| C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R |
| A00-B99: Certain infectious and parasitic diseases | Cryptosporidium infection | A07.2 | EGFR |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | INSR; IGF1R |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | INSR; MAPT; GSK3B |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hunter syndrome | E76.1 | INSR |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; CA4 |
| C00-D49: Neoplasms | Ocular cancer | C69 | APEX1 |
| C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | PLK1; AURKB; AURKA |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | EGFR |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT |
| C00-D49: Neoplasms | Locally advanced head and neck cancer | C07-C14, C32, C33 | EGFR |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | FLT4; EGFR |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | AKT1; INSR; CA9; EGFR; ERBB2; PLK1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | INSR |
| K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET |
| C00-D49: Neoplasms | Liver cancer | C22 | KDR; IGF1R |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | PTK2; BRAF; AURKA |
| C00-D49: Neoplasms | Late-stage non-small cell lung cancer | C33-C34 | EPHB4 |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | FLT4; MET; KDR; IGF1R |
| C00-D49: Neoplasms | HER2-positive urogenital cancer | NA | ERBB2 |
| C00-D49: Neoplasms | Hematologic malignancies | C81-C86 | AKT1 |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | SRC; CD38; AURKB |
| C00-D49: Neoplasms | Ovarian cancer | C56 | KDR; KDR; KDR; KDR; EGFR; EGFR |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | SRC |
| I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR |
| A00-B99: Certain infectious and parasitic diseases | Anthelmintic | B89 | ALPL |
| C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | EGFR |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chronic pain | R52.1-R52.2, G89 | ERBB2 |
| I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | TEK; SRC |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | CA1 |
| C00-D49: Neoplasms | Leukemia | C90-C95 | AKT1 |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | BRAF |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | AKT1; KDR; EGFR; PLK1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | MAPT |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2 |
| C00-D49: Neoplasms | Prostate cancer | C61 | FLT4; EGFR; ERBB2; PLK1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypercholesterolemia | E78 | INSR |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R |
| C00-D49: Neoplasms | Gastric cancer | C16 | KDR; KDR; EGFR; EGFR; ERBB2 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | TEK; KDR |
| I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET |
| C00-D49: Neoplasms | AML | NA | KDR |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | EGFR |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Myocardial reperfusion injury | T86.4 | AKT1 |
| C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET; PLK1; AURKA |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypoglycemia | E16.0-E16.2 | INSR |
| C00-D49: Neoplasms | Renal cancer | C64 | KDR; CA9 |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | KDR; KDR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 1/2 diabetes | E08-E13 | INSR |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAPT |
| C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR |
| C00-D49: Neoplasms | Refractory breast cancer | C50 | EGFR |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | EGFR |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | PDGFRB; MET; KDR; EGFR; EGFR; IGF1R; IGF1R |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | TEK |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperglycaemia in type 2 diabetes | E11, R73.9 | INSR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | INSR |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R |
| C00-D49: Neoplasms | Chronic myelogenous leukaemia | C92.1 | SRC |
| H00-H59: Diseases of the eye and adnexa | Retinal venous occlusion | H34.8 | ERBB2 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | AKR1B1 |
| C00-D49: Neoplasms | Non-hodgkin's lymphoma | C85 | ERBB2; PLK1 |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | ERBB2 |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | KDR; EGFR; EGFR; ERBB2; IGF1R |
| C00-D49: Neoplasms | Colon cancer | C50 | ALPL; EGFR |
| C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | FLT4; TEK; PDGFRB; AKT1; MET; KDR; KDR; KDR; SRC; CA9; EGFR; ERBB2; PLK1; PLK1; IGF1R; PTK2; AURKB; AURKA |
| G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R |
| C00-D49: Neoplasms | Multiple myeloma | C90 | SRC; CD38; IGF1R |
| C00-D49: Neoplasms | Glioma | C71 | KDR; EGFR; EGFR |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1 |
| C00-D49: Neoplasms | Thyroid cancer | C73 | KDR; BRAF |
| C00-D49: Neoplasms | Solid tumors | NA | BRAF |
| K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET |
| C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Vulnerary | S00-T98 | EGFR |
| NA: NA | Edema | NA | CA2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | IGF1R |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Pompe's disease | E74.02 | GAA |
| C00-D49: Neoplasms | Osteosarcoma | C40-C41 | SRC; GSK3B |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |